From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer. Issue 5 (8th September 2019)

Record Type:: Journal Article
Title:: From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer. Issue 5 (8th September 2019)
Main Title:: From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
Authors:: Pirker, Robert
Filipits, Martin
Abstract:
Is Part Of:: ESMO open. Volume 4:Issue 5(2019)
Journal:: ESMO open
Issue:: Volume 4:Issue 5(2019)
Issue Display:: Volume 4, Issue 5 (2019)
Year:: 2019
Volume:: 4
Issue:: 5
Issue Sort Value:: 2019-0004-0005-0000
Page Start:
Page End:
Publication Date:: 2019-09-08
Subjects:: alectinib -- anaplastic lymphoma kinase -- ALK inhibitors -- brigatinib -- ceritinib -- crizotinib -- lorlatinib -- tyrosine kinase inhibitors
Cancer -- Periodicals
616.994005
Journal URLs:: http://esmoopen.bmj.com/ ↗
https://www.esmoopen.com/current ↗
https://www.sciencedirect.com/journal/esmo-open ↗
http://www.bmj.com/archive ↗
DOI:: 10.1136/esmoopen-2019-000548 ↗
Languages:: English
ISSNs:: 2059-7029
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 22981.xml